Mucopolysaccharidoses in the Scandinavian countries: Incidence and prevalence

Acta Paediatrica, International Journal of Paediatrics

Volumn 97, Issue 11, 2008, Pages 1577-1581

  Malm, Gunilla ^a   Lund, Allan M ^b   Månsson, Jan Eric ^c   Heiberg, Arvid ^d  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Rigshospitalet   (Denmark)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Incidence; Mucopolysaccharidoses; Prevalence; Scandinavia

Indexed keywords

ARTICLE; CHILD; COST BENEFIT ANALYSIS; DENMARK; FEMALE; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MAROTEAUX LAMY SYNDROME; MORQUIO SYNDROME; NORWAY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SANFILIPPO SYNDROME; SCANDINAVIA; SWEDEN;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; INFANT; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSES; PREVALENCE; SCANDINAVIA; YOUNG ADULT;

EID: 53749104461     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2008.00965.x     Document Type: Article

References (22)

1. Neufeld EF, Joseph M. The Mucopolysaccharidoses. In : Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease. 8th ed. New York : McGraw-Hill, 2001 : 3421 52.
2. Bjoraker KJ, Delaney K, Peters C, Krivit W, Shapiro EG. Long-term outcomes of adaptive functions for children with mucopolysaccharidosis I (Hurler syndrome) treated with hematopoietic stem cell transplantation. J Dev Behav Pediatr 2006 27 : 290 6.
3. Boelens JJ, Wynn RF, O'Meara A, Veys P, Bertrand Y, Souillet G, et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007 40 : 225 33.
4. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002 49 : 359 78.
5. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD, et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996 87 : 4894 902.
6. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P, et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 2004 350 : 1960 9.
7. Ringden O, Remberger M, Persson U, Ljungman P, Aldener A, Andstrom E, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995 15 : 619 25.
8. Ringden O, Remberger M, Svahn BM, Barkholt L, Mattsson J, Aschan J, et al. Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. Transplantation 2006 81 : 718 25.
9. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, et al. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med 2005 7 : 143 6.
10. Kakkis ED, McEntee MF, Schmidtchen A, Neufeld EF, Ward DA, Gompf RE, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996 58 : 156 67.
11. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001 344 : 182 8.
12. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr 2004 144 : 581 8.
13. Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 2007 90 : 171 80.
14. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006 8 : 465 73.
15. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatrics 2008 167 : 267 77.
16. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 2005 115 : 681 9.
17. Beesley CE, Meaney CA, Greenland G, Adams V, Vellodi A, Young EP, et al. Mutational analysis of 85 mucopolysaccharidosis type I families: frequency of known mutations, identification of 17 novel mutations and in vitro expression of missense mutations. Hum Genet 2001 109 : 503 11.
18. Whiteman P. The quantitative measurement of Alcian blue-glycosaminoglycan complexes. Biochem J 1973 131 : 343 50.
19. Hopwood JJ, Muller V, Smithson A, Baggett N. A fluorometric assay using 4-methylumbelliferyl alpha-l-iduronide for the estimation of alpha-l-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin Chim Acta 1979 92 : 257 65.
20. Malm G, Bondeson ML, von Dobeln U, Mansson JE. Mucopolysaccharidoses. New therapeutic possibilities increase the need of early diagnosis. Lakartidningen 2002 99 : 1804 9.
21. Baehner F, Schmiedeskamp C, Krummenauer F, Miebach E, Bajbouj M, Whybra C, et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005 28 : 1011 7.
22. Vervoort R, Gitzelmann R, Bosshard N, Maire I, Liebaers I, Lissens W. Low beta-glucuronidase enzyme activity and mutations in the human beta-glucuronidase gene in mild mucopolysaccharidosis type VII, pseudodeficiency and a heterozygote. Hum Genet 1998 102 : 69 78.